Brand name: Meridia
Public Citizen has been assessing the quality and efficacy of drugs and devices since its founding in 1971. We use the law, petitions, and letters to monitor the FDA and coax the agency into action. Our actions have contributed to many drugs being pulled off the market. Public Citizen has also been instrumental in getting “black box” and other warnings on drugs. Our advocacy work on this drug is available below.
If you are interesting in reading our evaluations of the safety and efficacy of medications as well as information on drug side effects and interactions, please visit WorstPills.org.
More information on sibutramine (Meridia)
- Testimony Before FDA Endocrinologic and Metabolic Drugs Advisory Committee Meeting on Cardiovascular Risk Assessment of Obesity Drugs, March 29, 2012
- Position Statement: FDA’s Decision to Pull Diet Pill Sibutramine (Meridia) Commendable, But Took Too Long for Drug’s Victims, October 8, 2010
- Testimony on Sibutramine (Meridia), September 15, 2010
- Position Statement: Study Reinforces Long-Known Dangers of Weight-Loss Drug Sibutramine (Meridia), September 1, 2010
- Letter to FDA Praising Food Safety Cautiousness, Attacking Drug Safety Recklessness, March 8, 2010
- Petition to Ban Sibutramine (Meridia), December 3, 2009
- Statement on FDA Denial of Public Citizen’s Petition to Ban Sibutramine (Meridia), August 17, 2005
- Supplement to Petition to Ban Sibutramine (Meridia), September 3, 2003
- Letter Urging Prosecution of Abbott Laboratories for Withholding Information on Sibutramine (Meridia), May 21, 2002
- Petition to Ban the Diet Drug Sibutramine (Meridia), March 19, 2002